John Furey, Imvax CEO

A neu­ro­sur­geon spent the past 30 years de­vel­op­ing a neoanti­gen tu­mor vac­cine. Now he has $112M for a piv­otal test

As a neu­ro­sur­geon, David An­drews knew there wasn’t much he could do for his glioma pa­tients af­ter re­sect­ing — rarely ful­ly — their tu­mor. Even with the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.